Development of an Innovative in Vitro Potency Assay for Anti-Botulinum Antitoxins.
Botulinum neurotoxins are bacterial proteins that cause botulism, a life-threatening disease. Therapy relies mostly on post-intoxication antibody treatment. The only accepted method to measure the potency of, and to approve, antitoxin preparations is the mouse lethality neutralization bioassay. However, this assay is time-consuming, labor-intensive, costly, and raises ethical issues related to the large numbers of laboratory animals needed. Until now, all efforts to develop an alternative in vitro assay have not provided a valid replacement to the mouse potency assay. In the present study, we report the development of an innovative in vitro assay for determining botulinum antitoxin potency, using botulinum type B as a model. The concept of the assay is to mimic two fundamental steps in botulinum intoxication: receptor binding and catalytic activity. By simulating these steps in vitro we were able to accurately determine the potency of antitoxin preparations. The reproducibility of the assay was high with a CV < 13%. Most importantly, the antitoxin potency measured by the in vitro assay highly correlated with that measured by the standard in vivo mouse assay (r = 0.9842, p < 0.0001). Thus, this new in vitro assay has the potential to be considered, after validation, as a replacement to the mouse assay for quantitating neutralizing antibody concentrations in pharmaceutical botulinum antitoxin preparations. Future adoption of this in vitro assay would minimize the use of laboratory animals, speed up the time, and reduce the cost of botulinum antitoxin approval.
Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona 7410001, Israel. osnatr@iibr.gov.il.
Osnat
O
Rosen
Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona 7410001, Israel. eyalo@iibr.gov.il.
Eyal
E
Ozeri
Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona 7410001, Israel. adab@iibr.gov.il.
Ada
A
Barnea
Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona 7410001, Israel. alonb@iibr.gov.il.
Alon Ben
AB
David
Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona 7410001, Israel. ranz@iibr.gov.il.
Ran
R
Zichel
D000818:Animals; D057134:Antibodies, Neutralizing / Q000276:immunology* / Q000378:metabolism; D001681:Biological Assay; D001904:Botulinum Antitoxin / Q000276:immunology* / Q000378:metabolism; D019274:Botulinum Toxins, Type A / Q000276:immunology* / Q000378:metabolism; D002384:Catalysis; D010450:Endopeptidases / Q000378:metabolism; D066298:In Vitro Techniques; D051379:Mice; D010455:Peptides / Q000276:immunology / Q000378:metabolism
D057134:Antibodies, Neutralizing; D001904:Botulinum Antitoxin; D010455:Peptides; C096323:rimabotulinumtoxinB; D010450:Endopeptidases; D019274:Botulinum Toxins, Type A
anti-botulinum antibodies; botulinum; in vitro assay; potency
Anal Biochem. 2015 Mar 15;473:7-10
25277815
Appl Environ Microbiol. 1999 Sep;65(9):3787-92
10473376
Anal Biochem. 2014 Jul 1;456:50-2
24721293
J Infect Dis. 2014 Jan 15;209(2):183-91
24106296
J Clin Microbiol. 1996 Aug;34(8):1934-8
8818885
Clin Infect Dis. 2015 Dec 15;61(12):e58-61
26420800
Eur Neurol. 2001;45(4):257-60
11385265
J Biomol Screen. 2007 Apr;12(3):370-7
17332092
Anal Chem. 2005 Oct 1;77(19):6140-6
16194071
Physiol Rev. 2000 Apr;80(2):717-66
10747206
Biosens Bioelectron. 2011 Jan 15;26(5):1929-35
20650627
Neurology. 1998 Jun;50(6):1624-9
9633703
Nature. 2006 Dec 21;444(7122):1096-100
17167418
Anal Bioanal Chem. 2014 Nov;406(28):7149-61
25228079
J Immunol Methods. 2008 Aug 20;337(1):42-8
18571196
J Agric Food Chem. 2015 Jan 22;:null
25578960
Appl Environ Microbiol. 1992 Aug;58(8):2345-54
1514783
Science. 2006 Apr 28;312(5773):592-6
16543415
Clin Infect Dis. 2005 Oct 15;41(8):1167-73
16163636
J Infect Dis. 1984 Sep;150(3):407-12
6481185
Anal Chem. 2005 Jul 1;77(13):3916-24
15987092
Anal Chem. 2014 Nov 4;86(21):10847-54
25285509
Anal Biochem. 2011 May 1;412(1):67-73
21276417
Biochem Biophys Res Commun. 2008 Sep 19;374(2):331-5
18639519
FEBS Lett. 2007 Oct 16;581(25):4803-8
17889852
Biologicals. 2003 Mar;31(1):17-24
12623056
Clin Vaccine Immunol. 2010 May;17 (5):784-92
20357058
Neurology. 1998 May;50(5):1463-6
9596008
Emerg Infect Dis. 2005 Oct;11(10 ):1578-83
16318699
Trends Biochem Sci. 2002 Nov;27(11):552-8
12417130
Biochem Biophys Res Commun. 2011 Jan 7;404(1):388-92
21130748
Bull World Health Organ. 1963;29:701-9
14107742
Nature. 2006 Dec 21;444(7122):1092-5
17167421
Anal Biochem. 2006 Apr 1;351(1):84-92
16500606
J Pharmacol Toxicol Methods. 2010 May-Jun;61(3):304-10
20100585
Am J Med. 1984 May;76(5):794-8
6720725
JAMA. 2001 Feb 28;285(8):1059-70
11209178
FEBS Lett. 2012 Feb 17;586(4):310-3
22265973